S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Chimerix Stock Forecast, Price & News

+0.13 (+1.42 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $9.30
50-Day Range
MA: $9.52
52-Week Range
Now: $9.30
Volume806,443 shs
Average Volume1.41 million shs
Market Capitalization$582.50 million
P/E RatioN/A
Dividend YieldN/A
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Chimerix logo


Chimerix (CMRX) Q4 2020 Earnings Call Transcript
February 26, 2021 |  finance.yahoo.com
Steven Cohen Dives Into Chimerix - Yahoo Finance
February 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CMRX
Year FoundedN/A



Sales & Book Value

Annual Sales$12.52 million
Book Value$1.79 per share


Net Income$-112,580,000.00
Net Margins-321.31%


Market Cap$582.50 million
Next Earnings Date5/6/2021 (Estimated)


Overall MarketRank

1.35 out of 5 stars

Medical Sector

708th out of 1,972 stocks

Pharmaceutical Preparations Industry

337th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
+0.13 (+1.42 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

Is Chimerix a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chimerix stock.
View analyst ratings for Chimerix
or view top-rated stocks.

What stocks does MarketBeat like better than Chimerix?

Wall Street analysts have given Chimerix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chimerix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Chimerix

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. Chimerix had a negative trailing twelve-month return on equity of 36.57% and a negative net margin of 321.31%.
View Chimerix's earnings history

How has Chimerix's stock price been impacted by Coronavirus?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CMRX shares have increased by 545.8% and is now trading at $9.30.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CMRX?

2 analysts have issued twelve-month price targets for Chimerix's stock. Their forecasts range from $10.00 to $16.00. On average, they expect Chimerix's stock price to reach $13.00 in the next year. This suggests a possible upside of 39.8% from the stock's current price.
View analysts' price targets for Chimerix
or view top-rated stocks among Wall Street analysts.

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 55, Pay $869.4k)
  • Mr. Michael T. Andriole M.B.A., Chief Bus. Officer, Sec. & CFO (Age 48, Pay $539.79k)
  • Dr. Michael A. Alrutz, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51, Pay $619.5k)
  • Mr. David Jakeman, Exec. Director of Fin. & Accounting and Principal Accounting Officer (Age 44)
  • Dr. Roy W. Ware, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier, Chief Science Officer
  • Ms. Michelle LaSpaluto, VP of Strategic Planning & Investor Relations
  • Dr. Allen S. Melemed M.B.A., M.D., Chief Medical Officer

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (6.32%), BlackRock Inc. (6.15%), Renaissance Technologies LLC (4.69%), Dimensional Fund Advisors LP (3.63%), Ikarian Capital LLC (1.97%) and Northern Trust Corp (0.84%). Company insiders that own Chimerix stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix

Which institutional investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Diametric Capital LP, Prelude Capital Management LLC, Dimensional Fund Advisors LP, Citigroup Inc., Nuveen Asset Management LLC, Northern Trust Corp, and GSA Capital Partners LLP. Company insiders that have sold Chimerix company stock in the last year include David Jakeman, and Martha J Demski.
View insider buying and selling activity for Chimerix
or view top insider-selling stocks.

Which institutional investors are buying Chimerix stock?

CMRX stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., JPMorgan Chase & Co., State of Wisconsin Investment Board, Koshinski Asset Management Inc., Koshinski Asset Management Inc., Panagora Asset Management Inc., Vanguard Capital Wealth Advisors, and Bank of New York Mellon Corp. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix
or or view top insider-buying stocks.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $9.30.

How much money does Chimerix make?

Chimerix has a market capitalization of $582.50 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Chimerix have?

Chimerix employs 43 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

Where are Chimerix's headquarters?

Chimerix is headquartered at 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.